does bupropion carry a substantial seizure risk in anorexia and bulimia, and is it the electrolytes?
“adding buropropion on top of that carries a substantial risk of seizure.”
a host, a psychiatry resident said on PsychEd: Educational Psychiatry Podcast, 2026-10-01, at 12:40. hear it in context →
the episode: PsychEd Shorts 17: Medical Considerations in Eating Disorders (at 12:40). we link the show's own page; we do not re-host audio.
first, the part that holds
the core of this is right. bupropion carries an FDA contraindication for anyone with a current or past diagnosis of bulimia or anorexia nervosa because seizures were seen more often in these patients, and the trial that started it saw four grand mal seizures in a bupropion arm of 55 people with bulimia, a rate well above anything seen in earlier studies of the drug.
what we found when we went and looked
the current FDA label for extended-release bupropion (revised 11/2025) lists current or prior bulimia or anorexia nervosa as a contraindication "as a higher incidence of seizures was observed in such patients." the evidence behind it is a 1988 multicenter placebo-controlled trial in non-depressed people with bulimia: four people had grand mal seizures on bupropion, with 55 in the bupropion arm. against a label baseline of about 0.4% (13/3200) for immediate-release bupropion at 300-450 mg/day, that is a large excess, so "substantial" holds. the claim goes too far in its "because" clause. the trial authors recommended against the drug "pending a satisfactory explanation" for the seizures, and the label lists eating disorders and metabolic disorders as separate risk factors without giving a mechanism. the electrolyte explanation is a plausible hypothesis that gets stated as if it were established.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| adding bupropion in patients with bulimia nervosa carries a substantially increased seizure risk | confirmed | 1988 multicenter controlled trial: four grand mal seizures during bupropion treatment (bupropion arm n=55), 'a frequency of seizures far higher than observed in previous studies with this drug'. the label baseline for immediate-release bupropion at 300-450 mg/day is about 0.4%. limitation: a single small trial of the immediate-release form at older dosing, and the abstract does not say whether all four seizures came from the randomized arm [1][2] |
| the same increased seizure risk applies to anorexia nervosa | overstated | the FDA label puts anorexia nervosa under the same contraindication and lists it as a condition that raises seizure risk. but the only controlled data we read were in bulimia. we found no published anorexia-specific seizure incidence, so the 'substantial' magnitude has only been shown for bulimia [1][3] |
| the increased risk is because of metabolic disturbances (from the eating disorder) that lower seizure threshold | overstated | the trial authors gave no mechanism and advised against use 'pending a satisfactory explanation for the occurrence of these seizures'. the label lists 'metabolic disorders (e.g., hypoglycemia, hyponatremia...)' and 'anorexia nervosa or bulimia' as separate seizure risk factors and does not say one explains the other. the hypothesis is biologically plausible but has not been shown [1][2] |
| bupropion seizure risk depends on dose and on predisposing factors | confirmed | the label says risk is 'dose-related', estimates that incidence 'increases almost tenfold between 450 and 600 mg/day', and gives about 0.1% for sustained-release up to 300 mg/day. a 1989 review of manufacturer data found predisposing factors in more than half of 37 documented seizure cases [1] |
both directions
for the speaker: the FDA contraindication is explicit and covers both bulimia and anorexia nervosa, in current or past diagnosis. the founding trial's seizure count (four, in a 55-person bupropion arm) is many times the label's general-population rate for the same formulation. the label also names metabolic disorders such as hyponatremia and hypoglycemia as independent seizure risk factors, and those disturbances can occur with purging and restriction. so the proposed mechanism is coherent, even though nobody has proven it.
against: the trial's own authors said they had no satisfactory explanation for the seizures, so the "because of metabolic disturbances" clause states as fact something the primary record leaves open. the magnitude comes from one 1980s trial of the immediate-release form in bulimia. the label says outright that seizure incidence with the extended-release form "has not been formally evaluated in clinical trials." anorexia nervosa is in the contraindication, but we found no anorexia-specific seizure data showing the same size of risk.
what this cannot say
we read the trial abstract, not the full paper, so we cannot say whether the seizing patients had documented electrolyte abnormalities, what doses they were on, or whether any of the four came from an open-label phase. we did not find data on modern sustained- or extended-release bupropion in people with eating disorders. a contraindication can rest on a safety signal without a measured effect size, so the label confirms that the risk is taken seriously but does not tell us how big it is today. this check does not cover combination products containing bupropion.
sources, each one fetched and read
- US FDA, prescribing information, bupropion hydrochloride extended-release tablets (NDA 021515), revised 11/2025 What we read there: section 4: contraindicated 'in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients'. section 5.3: risk is dose-related; lists 'anorexia nervosa or bulimia' and separately 'metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia)'; incidence about 0.1% with sustained-release up to 300 mg/day and about 0.4% (13/3200) with immediate-release at 300-450 mg/day; 'increases almost tenfold between 450 and 600 mg/day'. Fetched 2026-10-20 (HTTP 200). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021515s049lbl.pdf
- multicenter trial group. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 1988;49(7):262-6. PMID 3134343 What we read there: double-blind placebo-controlled trial in non-depressed bulimia (bupropion n=55, placebo n=26); bupropion reduced binge eating and purging; 'four subjects experienced grand mal seizures during treatment with bupropion, a frequency of seizures far higher than observed in previous studies'; authors recommend it not be given alone to bulimic patients 'pending a satisfactory explanation for the occurrence of these seizures'. Fetched 2026-10-20 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/3134343/
- openFDA drug label API, generic bupropion hydrochloride extended-release tablets (XL) label, queried 2026-10-20 What we read there: contraindications: 'current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients'. lists metabolic disorders and anorexia nervosa or bulimia among seizure risk factors. Fetched 2026-10-20 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:"bupropion+hydrochloride"+AND+contraindications:anorexia&limit=1
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam